Site updated at Wednesday, 22 June 2016

Living with Dementia

Biomarkers in cerebrospinal fluid can identify patients with Alzheimer’s disease

  • - Dementia News
  • Oct 22, 2012
  • Comments
  • Viewed: 437
Tags: | alpha-synuclein | alzheimer's disease | alzheimer's disease biomarkers | beta-amyloid |

Analysis of specific biomarkers in a cerebrospinal fluid sample can differentiate patients with Alzheimer’s disease from those with other types of dementia. The method, which is being studied by researchers at Sahlgrenska Academy, may eventually permit earlier detection of Alzheimer’s disease.

Due to the similarity of the symptoms, differentiating patients with Alzheimer’s from those with other types of dementia - or patients with Parkinson disease from those with other motor disorders - is often difficult.

Making a proper diagnosis is essential if proper treatment and medication are to commence at an early stage. A research team at Sahlgrenska Academy, University of Gothenburg, is developing a new method to differentiate patients with Alzheimer’s disease or Parkinson disease by analyzing a cerebrospinal fluid sample.

The study, led by Professor Kaj Blennow and conducted among 450 patients at Skåne University Hospital and Sahlgrenska University Hospital, involved testing five proteins that serve as biomarkers for the two diseases.

“Previous studies have shown that Alzheimer’s disease is associated with biochemical changes in specific proteins of the brain,” says Annika Öhrfelt, a researcher at Sahlgrenska Academy. “This study has found that the inclusion of a new protein can differentiate patients with Alzheimer’s disease from those with Lewy body dementia, Parkinson disease dementia and other types of dementia.”

Similarly, the biomarkers can differentiate patients with Parkinson disease from those with atypical Parkinsonian disorders.

“Additional studies are needed before the biomarkers can be used in clinical practice during the early stages of disease,” says Öhrfelt, “but these results represent an important step along the way.”

The article, entitled “Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients with Dementia and/or Parkinsonian Disorders,” was published by the Journal of the American Medical Association.


Annika Öhrfelt, Researcher at Sahlgrenska Academy
Cell: +46 734-25 74 99
Landline: +46 31 343 24 06

The study analyzed the following proteins: beta-amyloid, tau (P-tau), alpha-synuclein and neurofilaments. Participating researchers from the University of Gothenburg: Annika Öhrfelt, Radu Constantinescu, Ulf Andreasson, Björn Holmberg, Henrik Zetterberg and Kaj Blennow.


Annika Öhrfelt
University of Gothenburg

Post a comment [ + Comment here + ]

There are no comments for this entry yet. [ + Comment here + ]

Your details

* Required field

Please enter the word you see in the image below:

Comments are moderated by our editors, so there may be a delay between submission and publication of your comment. Offensive or abusive comments will not be published.

Going Home (A short film on Dementia)

preparing for appointment1 - sahlgrenska academy1 - non-familial parkinson's1 - dbs1 - dementiaantipsychotic drugs1 - neurologic disorder1 - risk for cognitive decline1 - protein amyloid beta1 - mental impairment1 - treat alzheimer's1 - declines in memory1 - adam10 enzyme1 - mediterranean diet1 - executive function1 - physical discomfort1 - brain damage2 - dopamine deficiency1 - bmi2 - autism spectrum1 - humor therapy1 - mcr1 - dementia and down’s syndrome1 - granulin1 - gene therapy1 - harmful cholesterol1 - temporal orientation1 - dementia-related diseases1 - diagnose parkinson's1 - cognitive tests1 - short-term memory problems1 -